<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The recently described navigator proteins have a multifaceted role in cytoskeletal dynamics </plain></SENT>
<SENT sid="1" pm="."><plain>We report here on the relevance of one of them, navigator 3 (NAV3), in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We analysed changes in chromosome 12 and NAV3 copy number in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>/<z:mpath ids='MPATH_270'>adenoma</z:mpath> samples of 59 patients and in 6 CRC cell lines, using fluorescence in situ hybridisation, loss of heterozygosity, and array-CGH </plain></SENT>
<SENT sid="3" pm="."><plain>NAV3 target genes were identified by siRNA <z:mpath ids='MPATH_63'>depletion</z:mpath>, expression arrays, and immunohistochemistry </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: NAV3 deletion and chromosome 12 polysomy were detected in 30 and 70% of microsatellite stability (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>) <z:mp ids='MP_0002038'>carcinomas</z:mp>, in 23 and 30% of <z:mpath ids='MPATH_270'>adenomas</z:mpath> and in four of six <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines </plain></SENT>
<SENT sid="5" pm="."><plain>NAV3 amplification was found in 25% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> samples </plain></SENT>
<SENT sid="6" pm="."><plain>NAV3 alterations correlated with lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> colon cells, NAV3 silencing induced upregulation of interleukin 23 receptor (IL23R) and gonadotropin releasing hormone receptor </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> and microsatellite instability <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, IL23R immunoreactivity correlated with Dukes' staging and <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e>, whereas nuclear beta-catenin correlated with <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> only </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: NAV3 copy number changes are frequent in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and in <z:mpath ids='MPATH_270'>adenomas</z:mpath>, and upregulation of IL23R, following NAV3 silencing, strongly correlates with Dukes' staging and <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>This suggests that NAV3 has a role in linking tissue <z:mp ids='MP_0001845'>inflammation</z:mp> to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development in the colon </plain></SENT>
</text></document>